responsible business supplement success depends ability research develop innovative medicines vaccines consumer healthcare products make accessible people responsible waygsk responsible business supplement supplement gsk responsible business cover image working together health business workers like head nurse jacqueline mankenda gsk report key information save children directly reaching thousands approach responsible business children including alongside financial performance hardest reach communities within annual report supplementary document photo ivy lahonsave children provides additional context details progress responsible business commitments guide using report guide navigation buttons dynamic links full screen mode interactive pdf designed help click dynamic links access pdf set view full screen mode easily navigate report find go main contents relevant information within report online exit full screen mode press escape view information looking use tabs top full toolbar navigate sections search pdf printerfriendly pdf use print icon navigation print whole part document print printfriendly format go preceding go next return last visitedgsk responsible business supplement contents inside report approach health behaviour people planet ata summary assurance learn approach find developing read learn create find managing read key data responsible business innovative products embedding values inspiring supportive work environmental impacts embedded within business improving access healthcare throughout business environment encourages operations products patients around world including ways employees develop across life cycle reduce research develop sell capabilities achieve carbon emissions water use market products best waste chairmans statement approach approach approach approach data summary ceos statement open innovation ethical conduct protecting health carbon summary assurance wellbeing people statement responsible business developing vaccines promoting values sales water practice dont need kept cold marketing practices promoting inclusion reporting waste diversity commitments better access medicines transparency vaccines clinical research community volunteering creates change building products better rigorous patient meet needs consumer safety reducing child mortality minimising animal testing strengthening healthcare addressing human infrastructure rights impacts eliminating controlling ethical interactions neglected tropical diseases fighting malaria eradicating polio access antiretroviral treatment hiv gsk responsible business supplement chairmans statement gsks longstanding commitment responsible board continues monitor gsk external benchmarking business remains central companys benchmarks commitment responsible strategy reflect efforts business practice gsk topped improve corporate reporting access medicines index fourth topped index integrated information responsible consecutive time index measures every time since began business approach performance within performance top pharmaceutical annual report document responsible companies efforts improve access rejoined dow jones business supplement provides additional detail medicines healthcare developing sustainability index topics structured clearly countries company also reentered score putting set progress made dow jones sustainability index ranking us top sector responsible business commitments top companies sector environmental social assuring gsk operates responsibly priority environmental social governance criteria governance criteria sought responsible investors board committees particular corporate responsibility committee crc final letter chairman gsk score b retained chair crc oversight crc one reasons took role position cdps progress challenges across range belief significant value company ftse climate disclosure responsible business areas brings society time chairman leadership index seventh doubt pleased seen many changes included strategies drive innovation year recognition amount commercial success key need diseases impacting much progress whether delivery quality climate change developing world like malaria ebola companys rd organisation efforts improve data disclosed directly linked access medicines evolution well antibiotic resistance strategies commercial model coupled operating way improve access medicines vaccines strong commitment shareholder returns gsk remains pricing models building capacity pharmaceutical company meets changing capability africa partnership remain confident gsk deliver considerable achieved carbon expectations society save children longterm value returns shareholders yd eu ac r ng yw ea rer trusts carbon standard committee encouraged see value wider society future water standard cutting continued efforts evolve commercial model carbon emissions water use across operations globally new approach compensation sales representatives rolled worldwide work ongoing fundamentally change member ftsegood relationship doctors customers removing since perception conflict interest sir christopher gent chairmangsk responsible business supplement ceos statement despite challenges resulting continue look ways transform looking priority areas made good operating environment made sustained commercial model new approach progress employee gender diversity progress companys compensation sales representatives slightly increasing proportion women strategic priorities commitment rolled worldwide changes build management operate responsibly reforms started usa track rollout preventative two years ago pleased see healthcare programme employees particularly proud progress recent healthcare practitioner customer families reaching countries far commitments improve access medicines satisfaction research showing gsk year saw worlds first malaria also set ambitious targets carbon ranks first usa among peer group vaccine come another step closer water waste continue face value bring work adding submitted rtss candidate regulatory challenge reducing carbon footprint fully implemented approval committed make across value chain sales commitment stop paying doctors speak vaccine available profit price propellant based inhalers product behalf instead deliver information need biggest carbon footprint continue grow new multichannel system however met operational water also saw progress addressing believe changes use target year early cutting use affordability barriers access healthcare right thing also since extended tiered pricing approach competitive advantage follow initiatives prescription medicines asking countries finally efforts many operate clinical trial data transparency pay based national income early look fulfil commitment operate important us delivering also committed freeze vaccine prices expect people put values responsibly id like thank employees gavi graduating countries ten years heart decisions work partners continued support financial performance meets exceeds expectations society helped us address challenges deliver addition committed invest million believe commitment africa next five years aiming thats issues saw china last year substantial achievements year wholly disappointing provide portfolio relevant products develop responsible business taken significant steps rectify issues innovative pricing strategies support african identified chinese business apply bring longterm sustainable rd expertise increase local manufacturing appropriate lessons operations elsewhere capacity capability business benefit strengthen monitoring ethical saw critical public health emergency conduct given complexity sector outbreak ebola west africa challenges working global healthcare sir andrew witty demanded urgent response well continue face risks however chief executive officer providing humanitarian support affected continue believe robust systems regions accelerated development place presence markets improve candidate vaccine ebola unprecedented access medicine broader healthcare rate trials underwaygsk responsible business supplement approach responsible business practice approach embedding creating value society governance values conduct developing innovative products maximising robust governance structure committed valuesbased responsible business practice access delivers direct benefit patients place oversee approach responsible business expect employees based values backed consumers successfully business oversight integrated within act transparently respectfully integrity deliver profitable sustainable business core governance framework put interests patients strong governance performance turn allows us generate consumers first leaders responsible audit risk committee focuses strategic priorities value returns shareholders embedding culture decision making key business risk areas gsk including non reinvest business wider society benefits work ranges way underpinned since healthy people communities financial risks supported audit conduct research approach sales assurance team provides independent view essential building strong sustainable societies marketing way interact responsible business approach ie assurance senior management patients doctors policymakers also contribute significant value making board risk managed across continually direct indirect economic contributions group line agreed assurance plan code conduct accompanying listening stakeholders countries communities operate training seek ensure everyone gsk gsk also boardlevel corporate tax employment people understands put values practice better understand responsibility committee crc led charitable support encourage employees report chairman crc oversight expectations us concerns speak channels responsible business priorities approach responsible business across four extend high standards suppliers priorities responsible business areas focus meets four times year providing third party code conduct approach sit within context macroeconomic highlevel guidance reviews performance social trends impacting wider society progress commitments companies trends present opportunities challenges global healthcare companies like gsk governance structure systems report progress across four areas health board behaviour people planet chairman executive directors independent developed longerterm commitments nonexecutive directors across four areas report details progress commitments corporate corporate administration audit risk remuneration nominations responsibility finance transactions committee committee committee committee committee committeeour approach responsible business practice continued listening stakeholders well ongoing stakeholder engagement value engagement range external carry additional research determine stakeholders effective tool gaining current emerging issues help shape deeper insight societal trends approach responsible business expectations well offering us example undertook formal opportunity challenge assumptions materiality analysis gathering internal way work external perspectives key areas teams across gsk engage wide range considerable financial operational andor stakeholders daytoday interactions reputational impacts company see chart customers formal engagement governments right identified issues patient advocacy groups see relevant business focus efforts regular dialogue suppliers see high medium importance partners investors communicating gsk stakeholders employees responding feedback critical running business effectively helps us retain talented people see willing fundamentally change way things better meet stakeholder expectations examples include open innovation strategy stimulate research unmet medical needs see end low medium high direct payments doctors see changes way reward people see sredlohekats ot ecnatropmi gsk responsible business supplement prioritising material issues access healthcare ethical conduct transparency prod uct innovation clinical trials conduct r esponsible sales marketing intellectual property rights lobbying advocacy practices product safety quality energy climate change tax community investment diversity inclusion economic animal research anticounterfeiting contribution training development waste recycling privacy data security water use human rights labour ethical supplier standards talent attraction reward health safety wellbeing biodiversity security supply importance business successcommitments progress user key work track progressing well completed work needed get work ongoing able demonstrate clear commitment commitment schedule deliverables good progress completed towards completing commitment progress find commitment tracker progress lla rof htlaeh gsk responsible business supplement commitments aim address global health needs aligned strategic priorities values open innovation adapt open innovation rd model currently used diseases created worlds first open lab noncommunicable diseases africa developing world apply areas great unmet medical need working pharmaceutical companies academics conduct scientific challenge including infectious disease alzheimers disease major study dementia research continued working imis new drugs bad bugs collaboration related antibiotic research developing vaccines invest development vaccines dont require continuous refrigeration invested us million research enable critical liquid component used dont need making distribution easier less expensive malaria vaccine candidate remain stable hotter climates working kept cold bill melinda gates foundation better access embed flexible pricing strategy innovative business models extended tiered pricing approach prescription medicines well vaccines pages medicines prescription medicines vaccines increase usage among less able asking countries pay based wealth ability pay committed freeze vaccines access afford products vaccine prices gavi graduating countries ten years building products continue build core range products formats better meet needs worked partners develop inhaled form oxytocin prevent better meet needs people across globe including less able access afford women dying pregnancyrelated causes reformulate antiseptic used products mouthwash reduce newborn deaths reducing child continue invest innovative crosssector partnerships reduce child mortality continued partnership save children aims reach one million mortality children matched employee fundraising million launched second health innovation award obtained ema agreement pathway chlorhexidine gel established emergency response workstream strengthening continue work partners support development strengthening reinvested million profits least developed countries strengthen healthcare healthcare infrastructure anticipate could improve access healthcare healthcare systems partnered world health organisation infrastructure million underserved people vs international telecommunication union vodafone barclays others pilot innovative healthcare delivery systems eliminating help eliminate control ten neglected tropical diseases affect billion donated million albendazole tablets help eliminate lf control controlling neglected people including elimination lymphatic filariasis intestinal worms made progress towards identifying preclinical candidate tropical diseases continued investment rd ongoing product donations contribution combat leishmaniasis parasite collaboration university london declaration neglected tropical diseases dundee wellcome trust fighting malaria build year commitment contribute fight malaria filed worlds first malaria vaccine candidate rtss regulatory approval continued rd investment partnerships ground started phase iii trials tafenoquine treat p vivax malariacommitments progress continued user key progress find commitment tracker progress eradicating polio continue support objective eradicating polio providing delivered million doses oral polio vaccine via global polio eradication vaccines unicef achieved initiative countries need bringing total billion doses past years access viiv healthcare continue increase access medicines care entered agreement medicines patent pool accelerate access antiretroviral adults children living hiv around world help dolutegravir adults children countries hiv burden treatment hiv unaids achieve goal reaching million people globally highest antiretroviral treatment ruoivaheb ruo gsk responsible business supplement work track progressing well completed work needed get work ongoing able demonstrate clear commitment commitment schedule deliverables good progress completed towards completing commitment promoting values continue drive valuesbased approach sales marketing practices completed rollout new sales compensation model globally january sales marketing across world interests consumers patients core started work change engage healthcare professionals practices longer pay speak medicines also changed way support education doctors transparency transparent possible clinical trial data including publishing led development wwwclinicalstudydatarequestcom researchers clinical trial data clinical study reports without patientlevel data outcome trials medicines request access anonymised patient level data clinical trials conducted gsk within appropriate process making available gsk companies researchers access anonymised patient level data scientific enquiry rigorous patient continue ensure interests safety patients consumers developed third party oversight programme consolidate streamline consumer safety paramount importance way design undertake clinical trials approach managing thirdparty risk globally introduced fingerprint product quality assurance monitoring reporting adverse endtoend supply chain serialisation programme strengthen events ongoing product usage anticounterfeiting measures minimising animal rigorously challenge need animal studies work minimise impact launched strategic initiative potential reduce reliance animal testing animal welfare investing development alternative studies sharing studies continued looking new ways develop medicines using human cells animalbased data tissues together european bioinformatics institute sanger institute promoting human address un guiding principles business human rights across increased focus human rights impacts identified external assessment rights operations supplier relationships business example global third party oversight programme engaging patient demonstrate gsk interactions patient advocacy groups political enhanced global standard operating procedures public policy group advocacy groups stakeholders conducted appropriately ethically transparently government official engagement first full year implementation emerging markets political stakeholders australasia patient advocacy strategy broaden deepen interactions patient groups whilst embedding highest levels transparency governancecommitments progress continued user key progress find commitment tracker progress protecting health continue create working environment inspires people grow provided preventive healthcare employees families wellbeing perform healthy resilient way countries employees participated programmes improve people personal resilience injury illness rate elpoep ruo promoting inclusion continue promote inclusion diversity globally gsk increased proportion women management developing diversity global standards measure businesses disability performance community extend volunteering opportunities bring positive change communities employees volunteered nonprofit organisations pulse volunteering global health providing individual development programme established volunteer ambassador network countries create change develop locally relevant programmes tenalp ruo gsk responsible business supplement work track progressing well completed work needed get work ongoing able demonstrate clear commitment commitment schedule deliverables good progress completed towards completing commitment aiming carbon reduce overall carbon footprint vs carbon cut scope emissions operations since neutral neutral value chain since scope emissions remains challenge sales propellant based inhalers continue grow reducing water reduce water impact across value chain vs cut operational water use since hitting impact target year early completed fouryear assessment measure water impact across value chain recertified carbon trusts water standard reducing waste reduce operational waste vs generated tonnes waste operations less less sent waste landfill compared sites achieved zero waste landfill building build sustainable supply lines nutrition portfolio work local farmers remain committed building sustainable supply chain nutrition sustainability improve agricultural practices improve yields competitiveness review portfolio changes market dynamics within portfolio impacting supply chain livelihoods sourcing model currently reviewing commitmentgsk responsible business supplement h ealth konnah family live community near monrovia badly affected ebola konnah lost family members virus remaining family helped save children gsk contributing fight ebola accelerating development investigational vaccine supporting humanitarian efforts including funding save children enable continue work name changed protect identitygsk responsible business supplement health approach health challenges remain medicines vaccines consumer health improving access availability products improving quality life patients aim extend access existing products focus contribution fundamental barrier consumers around world millions tackling affordability availability barriers fight ebola economic development people still getting vaccines tiered pricing approach prescription treatments need afford gsk working closely world quality life gsk medicines vaccines countries pay still many diseases without health organization regulators different prices based ability pay aims make real treatments impact poorest many partners respond ebola crisis determined gross national income gni per countries continue underresourced accelerate development investigational contribution meeting health systems capita maximise patient benefits sustain ebola vaccine also contributing business least developed countries challenges play part tackling global health ldcs capped prices overall humanitarian effort challenges using open innovation developed countries also february investigational ebola target unmet medical needs pioneering new investing new formulations distribution vaccine tested large phase iii business models increase access models make products available clinical trial sponsored national institute products collaborating strengthen health nih liberia protects volunteers developing countries bear greatest burden healthcare infrastructure hoped could contribute significantly infectious noncommunicable diseases making important contribution controlling outbreak future use mass ncds least resources manage millennium development goals vaccination campaigns depend whether africa many global health regulators stakeholders innovation challenges magnified investing satisfied vaccine candidate provides gsk scientists creating new products million stimulate research improve protection ebola without causing potential make real difference scientific capabilities build manufacturing significant side effects quickly large peoples lives around new molecular capacities see quantities vaccine made entities phase ii phase iii development strengthening healthcare systems following five approvals received actively exploring relevant worlds poorest countries lack four significant product approvals organisations partners opportunities trained healthcare workers diagnose diseases respiratory hiv diabetes accelerate development manufacturing administer treatment preventing many industrial scale trials know cant discover everything patients accessing medicines successful position significantly collaborate partners vaccines regardless cost rampup production vaccine candidate target unmet medical needs great reinvesting profits ldcs train help combat future ebola outbreaks scientific challenges diseases frontline healthcare workers aim improve impact developing world alzheimers access healthcare million people antibiotic resistance healthcare workers adapted approach intellectual partners trained past five years property accelerate discovery new drugs already providing access healthcare pressing health priorities malaria million people tb open innovation strategy offers external scientists access compound library resources promote research areasgsk responsible business supplement health approach continued investing africa gsk investing africa increase access goal deliver highimpact research projects medicines build capacity deliver sustainable contribute world health organisations global growth vision make gsk products available target reduction preventable ncd deaths population subsaharan africa ncd open lab builds success ldcs original open lab spain focuses malaria tuberculosis tb tropical diseases africa long borne highest rates infectious see diseases faces growing incidences ncds dual health burden poses significant trust science africa programme obstacle economic social development continue seek best scientific ideas fund development awarded funding six invest million africa next scientists kenya uganda research hiv five years working partners aim provide tb ncds africa see website portfolio relevant products innovative pricing trust science africa latin america strategies support african rd expertise increase local manufacturing capacity capability developing products needed increasing capability capacity manufacture supporting open innovation collaboration medicines africa create jobs boost longterm investing million create worlds economic prospects invest million first africa open lab ncd research gsk expand existing facilities kenya nigeria scientists external researchers work together build new factories elsewhere ensure sustainable improve understanding ncd variations production medicines africa african people african patients increase regions skills base aim establish academic chairsprogrammes promote study pharmaceutical science healthcare policy provision time enhance local research manufacturing healthcare capability helping secure future investment build vibrant healthcare economiesgsk responsible business supplement health open innovation adapting innovation opened innovation process noncommunicable diseases ncds urgent need develop new antibiotics accelerate research treatments diseases claiming lives ncds cancer effectively target bacteria widely model aim stimulate developing world accepting heart disease respiratory problems kidney recognised unique scientific challenges research needed potential commercial return disease diabetes worlds biggest lengthy complex clinical trials low rd investment applying killers strategic approach ncds includes return investment hampered attempts open innovation model target unmet innovation research new drugs improving address need many companies medical needs overcome significant scientific efficacy existing medicines increasing withdrawn area combining challenges alzheimers antibiotics patient access medicines health long heritage expertise antibiotics education prevention products open innovation approach stimulate open innovation approach commitment adapt open innovation help people quit smoking example research antibiotic resistance well approach based three principles rd model currently used diseases approach ncds see policy paper advocating global action access compounds data greater developing world apply areas using open innovation approach flexibility intellectual property well inhouse team researchers great unmet medical need scientific promote research new treatments ncds partnerships share expertise processes investigating potential new antibiotics challenge including infectious disease alzheimers disease infrastructure nearly ncdrelated premature deaths collaborate others innovative occur low middleincome countries medicines initiatives imis new drugs bad screened entire library march part africa strategy bugs ndbb programme two million compounds signs activity announced million investment establish malaria tb two worlds contributed five projects within progress overview progressing well worlds first africa ncd open lab address deadliest infectious diseases shared ndbb programme ranging design specific variations ncds africa compounds data wider scientific implementation efficient clinical trials innovative research network see gsk scientists community stimulate research areas understanding design compounds collaborate researchers across africa high also aim share results similar penetrate multidrugresistant pathogens quality research hub rd facility screening exercises several neglected stevenage uk gsk medical research alzheimers dementia tropical diseases near future councils south africa uk together extending open innovation approach external researchers working alongside gsk pledged million help south african target alzheimers dementia gsk part scientists open lab tres cantos researchers study ncds part open dementias platform uk million spain access compound library lab initiative part first call proposals partnership pharmaceutical companies facilities financial support tres november committed million academics conducting large study cantos open lab foundation independent support successful proposals ncd research dementia research collaboration focuses charity million funding gsk cameroon cte divoire ghana kenya developing treatment also earlier projects open lab focus diseases malawi nigeria gambia uganda detection prevention disease developing world visiting tackling antibiotic resistance also working identify indicators scientists made use open lab discovery antibiotics revolutionised alzheimers disease participation built portfolio research projects since modern medicine patients longer die accelerating medicines partnership established minor infections efficacy medical national institutes health peer companies mainstay increasingly threatened steady academics rise bacteria immune antibiotics antibioticresistant bacteria mrsa causes deaths year eu alonegsk responsible business supplement health developing vaccines dont need kept cold working partners vaccines often need kept cold make exploring number different sure degrade transport approaches ultimate target keep help overcome barriers storage keeping refrigerated every step vaccine stable three years c delivering vaccines way tremendous challenge particularly amongst approaches considered developing countries vaccines play spray drying approach used extensively developing countries important role food manufacturing previously used manufacturing vaccines work inadequate equipment unreliable power bill melinda gates foundation supplies lack resources monitoring vaccines discovery partnership together temperatures make difficult maintain investing million research enable cold chain vaccines gsk adjuvant critical liquid component used commitment invest development recipient cold chain begins rtss candidate malaria vaccine remain vaccines dont require continuous manufacturing plant vaccine stable higher temperatures eventually refrigeration making distribution easier transferred destination country using make easier transport vaccine less expensive refrigerated unit upon arrival often subsaharan african regions disease challenges transferring vaccine prevalent see sometimes involves cool boxes taken boat malaria vaccine remote islands donkey small villages progress overview progressing well mountains reducing dependence made good progress towards cold chain big step forward objective currently evaluating delivery sustainable vaccination programmes findings could incorporated development future vaccines including candidate tb vaccinegsk responsible business supplement health better access medicines vaccines want medicines improve access healthcare reserve lowest vaccine prices catch programme strategies address affordability building local gavi publicprivate alliance improve access products approved europe usa vaccines accessible capacity supporting vulnerable communities vaccines worlds poorest countries also seek approvals developing countries everyone needs gavi supports countries gni per head significant unmet medical need affordability less countries develop appropriate permitted matter live improve affordability tiered pricing exceed gni threshold graduate national regulations combat rising strategy enables us offer products much afford gavi support committed freeze prevalence respiratory diseases prices take account economic factors vaccine prices graduating countries ten chronic obstructive pulmonary disease copd country years help maintain commitment asthma making nonpatented means ask countries pay fair price immunisation transition established medicines ventolin medicines vaccines based flixotide newly launched patented committed provide gavi wealth determined gross national income medicines relvar anoro million vaccine doses reduced commitment embed flexible gni per capita enable broad access affordable help us achieving goal prices help protect million children pricing strategy innovative business product globally prices least increasing access respiratory medicines developing world supply gavi models prescription medicines developed countries ldcs represent relevant patients developing countries vaccines rotavirus rotarix pneumococcal vaccines increase usage among lowest tiers additional tiers defined disease synflorix cervical cancer middle income countries national incomes less able access afford products lower upper middle high income cervarix cervarix used gavi higher often significant portion countries rather onesizefitsall demonstration projects three african countries population afford medicines approach within tier allow country understand effective way immunise tiered pricing approach means units develop local pricing strategies take progress overview progressing well girls entered threeyear offer innovative patient access programmes account economic factors countrys agreement supply lowcost doses example india introduced programme healthcare system patient affordability synflorix vaccine mdecins sans frontires offering eligible patients suffering committed extend tiered immunise children caught ongoing crises chronic idiopathic thrombocytopenic purpura pricing approach include prescription also continue work pan american autoimmune condition four weeks medicines well vaccines health organization bill melinda treatment free charge receive also cap prices patented medicines gates foundation supply cervarix countries week course revolade vaccines ldcs prices charged latin america caribbean lower developed countries long prices support longterm vaccination manufacturing costs covered programmes cervical cancer sustain prices long term since adopted approach increased amount medicines supply ldcs yemen example reduced price medicines average sales volumes increased gsk responsible business supplement health better access medicines vaccines continued developed markets important building local capability capacity support included also mindful burden healthcare costs promote local manufacturing developing giving cash donated million europe tailor approach specific countries joint ventures technology cash improve health wellbeing country needs work governments transfer arrangements help build capabilities communities worldwide example demonstrate value patients payers developing countries research donating million strengthen cash healthcare professionals taxpayers manufacture vaccines medicines product healthcare infrastructure ldcs primarily industry example uk price increasing access markets inkind respiratory medicines anoro relvar incruse training community health workers time examples include investing develop skills see management asthma copd line less infrastructure rd manufacturing capability alternatives usa list price product donations donated medicines total part new africa strategy see newly launched diabetes medicine tanzeum valued million support includes lower medicines class brazil partner fiocruz leading patient assistance programme public health research institution manufacture accounted total giving also offer patient assistance programmes vaccines address countrys public health million albendazole tablets paps eligible us patients priorities develop vaccine dengue fever fight lymphatic filariasis soiltransmitted insurance paps provided helminths see product donations prescribed gsk medicines vaccines valued india joint venture biological e support humanitarian aid countries million million nearly indian biotechnology company developing distributed partners americares patients overall patient enrolment declined sixinone combination vaccine containing direct relief ima world health map gsks patient assistance programme primarily inactivated poliovirus vaccine ipv international project hope result new coverage options available supporting vulnerable communities patients via affordable care act even time also encourage employees improve access healthcare people new coverage options us gsk volunteer time expertise see vulnerable communities make targeted continues help support patient access employee volunteering time accounted product financial donations programmes medicines also provides services help million run local global partners designed interested potentially eligible enrollees sustainable long term understand alternative coverage options global community investment totalled million million compared million million overall total contribution represents decline largely due fewer us patients enrolling gsks patient assistance programmes primarily result affordable care act gsk values product donations cost goods believe truer reflection cost gsk wholesale acquisition cost often used pharma industry valuing product donations total value product donations based wholesale acquisition cost milliongsk responsible business supplement health building products better meet needs aim better meet improving access products developing countries risk women dying india many lowincome rural making affordable also making pregnancyrelated causes times consumers live hardtoreach places needs people worldwide sure right type products available higher developed economies significantly expanded distribution network developing new products right places meet patient needs single biggest cause death excessive cover villages directly bleeding oxytocin manufactured hormone range wellness oral health nutritional formulations formats continued develop new formats used stop bleeding products appropriate size price range medicines consumer products requires refrigeration trained healthcare everyday purchase consumption many middleincome patients living worker administer product often also trained local women set respiratory conditions asthma lacking resourcepoor countries businesses sell products households copd afford sophisticated multidose launched multisector partnership develop areas retailers inhalers created new inhaler product inhaled form oxytocin designed commitment continue build core also launched singleserve sachets using singledose capsules ventolin rotacaps heatstable affordable easy administer range products formats better sensodyne toothpaste philippines sold small pack sizes spread meet needs people across globe reduce newborn deaths accelerating usa offer smaller oneweek supply cost ventolin rotacaps widely including less able access development common antiseptic found number smoking cessation products distributed gsk product philippines afford products corsodyl mouthwash prevent umbilical developing similar singledose cord infection leading sepsis capsules another respiratory partnership save children see medicines seretide progress overview track viiv healthcare began new collaboration janssen develop twodrug singletablet regimen patients already virally suppressed threedrug regimen plans include investigating potential paediatric fixeddose formulations regimen see gsk responsible business supplement health reducing child mortality innovative partnerships global efforts tackle child mortality june launched second annual many medicines recommended almost halved death rates among underfives million healthcare innovation award paediatric use including treatments asthma aim save lives since six million children still died save children identify innovations cancer eczema epilepsy hivaids children increasing fifth birthday improve survival rates among children infectious diseases albendazole tablet low middleincome countries mainly newborns particular developing countries donations supporting whos goal access essential vaccines preventable diseases two organisations jointly awarded deworm schoolage children medicines top prize university countries intestinal worms endemic vaccines medicines consumer healthcare nairobi received recognition barcoded see building commitment products expertise play important wellness cards register babies paediatric hiv viiv healthcare actively role reducing child mortality clinic born encourages carers investigating childfriendly formulations partnering save one million lives keep vaccinations ongoing care dolutegravir could add number partnering save children adding credit food products visit medicines available children living hiv commitment continue invest combine scientific expertise global clinic colalife based zambia see information innovative crosssector partnerships reach charitys child health expertise recognised innovative business model reduce child mortality ontheground knowledge together breaks lastmile barriers aim help save lives one million access medicines even remote areas children worlds poorest countries gsk employees contributing time progress overview track partnership formed exploring expertise enthusiasm support one existing products chlorhexidine partnership save children could used reduce deaths among infants volunteering fundraising match reformulating antiseptic used employee fundraising million year corsodyl mouthwash umbilical cord care first million reached september prevent serious infection common cause funds raised employees death many newborns used support programme pilot innovative approach improving care together investing flagship programmes premature babies kenya democratic republic congo drc kenya aim tackle challenges immunising treating children supply demand effective healthcare around worlds children contribute reduction maternal newborn immunised least one serious disease underfive deaths programmes focus gsk vaccine supply vaccines strengthening local health facilities gavi significantly reduced prices use services capacity building frontline worlds poorest countries see health workers community mobilisation committed provide gavi completed catch vaccination million vaccine doses reduced programme drc children prices help protect million children hardtoreach rural areas developing world photo jonathan hyamssave childrengsk responsible business supplement health strengthening healthcare infrastructure gsk committed together partners training projects undertaken include children mozambique healthcare workers exploring innovative registered mvaccination pilot strengthening health training nurses using innovative distance delivery models improve access programme vodafone seeks elearning tanzania amref health africa systems improve healthcare million people improve vaccination rates using mobile phones advocacy initiatives save children mobile app reminds caregivers access healthcare reinvesting healthcare focused ministry health officials vaccines due enables government reinvest profits sales developing countries pharmaceutical consumer healthcare members parliament burkina faso healthcare workers better manage vaccine stocks vaccination visits products ldcs strengthening training health workers care already recorded completed healthcare systems invested million international rural bangladesh reaching initial research five clinics expand based profits total million beneficiaries service clinics oneyear pilot million since reinvestment gsk also supports one million community funding usaid gavi programme began commitment continue work partners health workers campaign led un pilot measure impact assess cost support strengthening healthcare training key focus chronic shortage sustainable development network train effectiveness inform decisions scaling infrastructure anticipate could trained healthcare workers one main million community health workers end programme mozambique improve access healthcare million barriers providing effective healthcare investment helps track progress african countries underserved people vs remote regions working partners towards goal virtual operations mobile technology also heart major amref health africa care international room also enable users share best collaboration joined save children trained practices successes challenges international telecommunication union frontline healthcare workers far ldcs progress overview progressing well partnering develop new healthcare combat ncds around world better health across africa asia caribbean delivery models information education preventive measures community health workers doctors midwives exploring ways improve access play essential role reducing global nurses volunteers turn reached healthcare promote economic development incidence ncds addressing common million people example million threeyear risk factors including smoking alcohol poor diet reinvestment programmes partnership barclays zambia one year inactivity health ncds develop work partners educate communities finalising plans test feasibility scale best practices online healthcare health also work governments new social enterprise model increase including reminders support patients advocate investment healthcare see availability health services products tips avoid risk factors technical support website summary reinvestment underserved regions well plans pilot healthcare providers programmes country micro health insurance product improved affordability essential medicinesgsk responsible business supplement health eliminating controlling neglected tropical diseases committed ntds affect billion people albendazole donation researching new treatments worlds poorest communities cause gsk donated five billion urgent need new treatments combat defeating neglected tropical disability disfiguration death stretch albendazole tablets help eliminate lf ntds requires flexible open approach diseases ntds free healthcare budgets severely constrain control intestinal worms past years innovation gsk founding member wipo development opportunities donations reached million research open innovation platform future generations people including million children seeks accelerate development new extensive burden ntds requires debilitating impacts countries completed mass drug better treatments ntds dengue coordinated response improve access administration campaigns lf researchers rabies chagas disease well malaria existing treatments stimulate research estimate number people risk infection tb none currently exist gsk partner lf almost halved since london declaration joining bill melinda research development facility tres gates foundation pharmaceutical million people infected lf cantos spain see prioritises research companies donors national governments million living pain stigma ntds diseases developing commitment help eliminate control commitment work together control debilitating swelling causes intestinal world research yielded ten ntds affect billion people eliminate ntds worms infect million children worldwide including elimination progress towards identifying preclinical leading work first mile supply symptoms stunt development lymphatic filariasis lf candidate combat leishmaniasis parasite chain ensure efficient forecasting manufacturing prevent going school continued investment rd ongoing collaboration university shipping donated products annual product donations contribution donated albendazole tablets dundee wellcome trust scorecard details progress made london declaration ntds support efforts eliminate lf countries london declaration partners highquality hits african contribute whos goal regularly trypanosomiasis sleeping sickness focus contribution make deworm schoolage children screening million compounds biggest difference product donations countries intestinal worms endemic progress overview progressing well gsk compound library albendazole target lf soiltransmitted donated million albendazole helminths intestinal worms use tablets lf elimination million tablets promising hit compound library open innovation strategy promote research treat intestinal worms chagas disease identified open new treatments ntds lab collaboration new york university taken forward next stage total drug discovery process albendazole tablet donations since set compounds assembled tablets lf elimination ntds made available tablets treat intestinal worms wider scientific community rd total gsk responsible business supplement health fighting malaria supported malaria responsible gsk invested hundreds millions dollars promoting preventive measures deaths year around billion people date rtss programme also received african malaria partnership fight malaria risk spread mosquitos around estimated funding bill melinda gates foundation invested million since years researching new deaths malaria occur subsaharan africa addition international nonprofit organisation support community programmes ssa children path contributed financial scientific managerial aim prevent malaria training health workers treatments promoting age five field expertise development rtss volunteers distributing insecticidetreated preventive measures date licensed vaccine available gsk committed set eventual price bed nets promoting awareness campaigns prevention malaria gsk reached major rtss profit price cover cost work nonprofit partners deliver treated bed nets milestone submission regulatory manufacturing vaccine together small support ground communities sub application candidate malaria vaccine return around reinvested rd saharan africa rtss european medicines agency ema second generation malaria vaccines vaccines sierra leone example work tropical diseases key moment gsks year journey tony blair faith foundation reached develop worlds first malaria vaccine researching new treatments two million people population commitment build year submission follows announcement addition work vaccine prevent training religious leaders turn train commitment contribute fight phase iii data showing rtss almost halved spread malaria exploring effective community volunteers malaria prevention malaria continued rd investment number cases clinical malaria young treatments contract disease estimated households children aged months first vaccination partnerships ground changed behaviour result gsk pulse gsk researchers working collaboration months vaccination volunteers exploring opportunities replicate medicines malaria venture mmv positive opinion ema granted develop tafenoquine singledose medicine model parts africa indicated policy recommendation progress overview progressing well treatment p vivax malaria strain longstanding partnership carter may possible end positive widespread south south east asia latin center nigeria provides insecticidetreated bed opinion ema also basis marketing america horn africa latest stage nets educates people use authorisation applications ssa tafenoquine clinical trial announced effectively tackle malaria lf also rtss development involved one biggest april assess drugs efficacy transmitted mosquitos ghana support vaccine trials ever conducted africa safety adult patients successful tafenoquine family health international fhi training number additional steps still need could contribute significantly eliminating community health workers volunteers completed anticipate vaccine could malaria preventing relapses dormant diagnosis treatment management malaria available implementation early adopter p vivax parasite ntds onchocerciasis ssa countries schistosomiasis intestinal worms also working projects find new drugs p falciparum malaria treatment approach next phase preclinical discovery development end gsk responsible business supplement health eradicating polio gsk played key role war polio led global polio opv contains small quantity weakened eradication initiative gpei eradicated live polio virus phased countries read online tackling polio past disease many countries cut global polio already eradicated years remain incidence rate past years prevent small risk disease publish detail online key reemerging vaccine instead committed supporting eliminating final proving extremely issues including countries administer inactivated polio challenging india declared poliofree whos goal completely vaccine ipv ensure longterm supply clinical trials developing world milestone global health experts eradicate disease enn dce e mth ico u ing h f gu hn aa nc ih si te av na b nle ig eb ru iat p ano dlio p r ae km isa ti ns io nf ap nl eio w v ipc vci n fae cs l iw tye na r vv es bin eg l g iu wm hil elio ren tee cv nl oo lp oi gng tw rao nr sld fe v raccine production production due begin new outbreaks across africa ip access medicines middle east already produce supply ipv developing countries developed countries exploring ways vaccines recognised pandemic preparedness developing make accessible affordable vital eradication effort countries commitment continue support developing countries joint venture delivered million doses oral objective eradicating polio biological e indian pharmaceutical technology transfer capacity building polio vaccine opv via gpei countries providing vaccines unicef company creating combination vaccine developing countries needed contributed achieved includes ipv vaccines five billion doses since expect working together health mothers meet least unicefs demand diseases single dose expect children available anticipated billion doses gsk briefing noncommunicable diseases progress overview track also stockpiled large amounts developing world opv kept available use unicef gsk position statement post event outbreak development agenda approach pricing product donations working together health mothers childrengsk responsible business supplement health access antiretroviral treatment hiv contributing global efforts including important contributions viiv healthcare conducted collaborative children generic manufacturers viiv healthcare helped reduce research trials subsaharan africa assess royaltyfree voluntary licence develop paediatric global effort tackle hiv infection rates since treat people living hiv formulations dolutegravir countries hivaids viiv aidsrelated deaths since resources scarce including issues children hiv live licence also around million people worldwide mothertochild hiv transmission paediatric includes paediatric formulations lowerdose healthcare specialist still living hiv million died adult treatment strategies implications tablets currently clinical development hiv company owned aidsrelated causes hiv hepatitis b tuberculosis coinfection improving outcomes key affected delivering new treatments increasing access hiv treatment care populations gsk pfizer shionogi viiv healthcare granted approval nearly people infected hiv living vulnerable marginalised populations eu innovative antiretroviral treatment lowincome countries increasing access care sex workers men sex tivicay tivicay brand name compound treatment priority viiv healthcare applies men imperative access therapy dolutegravir integrase inhibitor used uniform approach medicines care combined support community combination antiretroviral medicinal goal supporting people countries based services combat stigma provide commitment viiv healthcare products treatment adults affected hiv royaltyfree voluntary licences support viiv healthcare works several continue research new treatments adolescents living hiv trials shown offered lowincome leastdeveloped partners positive action initiatives increase access medicines care tivicay effective treatmentnave subsaharan african countries middleincome meet needs communities adults children living hiv around experienced patients cited countries apply flexible pricing policy another vulnerable group million world also work communities dolutegravir longterm developmental factors gross domestic product impact children living hiv combat stigma discrimination associated priority child antiretroviral treatments epidemic country subsaharan africa hiv help world health combining antiretrovirals single pill fourteen royaltyfree licence agreements access appropriate treatment treating organization unaids achieve improves convenience patients generic manufacturing companies enable children requires appropriate formulations goal reaching million people viiv healthcare secured approval usa international manufacturers produce metabolic rates feeding globally antiretroviral treatment europe new singlepill treatment market lowcost versions viiv habits differ adults viiv healthcare works known triumeq combines dolutegravir healthcares antiretrovirals donor agency partners develop appropriate formulations nucleoside reverse transcriptase inhibitors publicsector programmes low prices including paediatric oral solutions progress overview progressing well pb aa rtc na ev ri ir n gn wd il ta hm ji av nu sd sin ee n tv oi dv e h vee la olt ph c aa nr de sis tu dls months regulatory approvals ten nd rm esa es ak cd h fl tra iv ao lsu sd es slu et dio n p e tric twodrug single tablet combining dolutegravir viiv healthcare entered agreement adolescent patients worldwide rilpivirine nonnucleoside reverse medicines patent pool mpp accelerate transcriptase inhibitor patients already access dolutegravir adults past five years viiv healthcares virally suppressed threedrug regimen children countries hiv burden positive action children fund invested highest adults viiv healthcare granted million programmes second study began royaltyfree licences leastdeveloped subsaharan africa help prevent mothers experimental longacting injectable integrase lowincome subsaharan african countries passing hiv children million inhibitor cabotegravir also known gsk introducing firstever mpp licence paediatric seed fund viiv healthcare also collaborating tiered royalty structure small janssen study cabotegravirs efficacy see viiv healthcare website percentage price based gdp safety tolerability combined information specific middleincome countries longacting form rilpivirine patients virally suppressedgsk responsible business supplement behaviour work put core values patient focus integrity respect people transparency heart every decision make embedding ethical behaviour across business code conduct training speak culture including stevenage site umesh kumar worksgsk responsible business supplement behaviour approach changing values ensuring employees expect employees third parties understand expectations focus code conduct way work work act according values aim create workplace everyone embed values patient focus integrity respect people feels valued respected empowered updated code reinforce transparency make right decisions wherever work critical role values play protecting everything want employees understand reputation commercial success want understand possible strengthened message employees expectations ethical behaviour exceed societys expectations us feel protected empowered report confidence report concerns code changed way business often going concerns confidential speak conduct available languages beyond industry norms embed channels part drive enhance created resource centre tools values thirdparty oversight extended code discussion guides help link values local cover complementary workforce research practices advance medical activities cultures science increased access data training code conduct already employees failing complete mandatory training clinical research trials including mandatory employees also time subject disciplinary action providing researchers anonymised required complementary workers defined permitted local labour laws patientlevel information see designated managers also fulfil annual sales marketing practices ethical leadership certification requirement fundamentally changed compensation ensure lead example create model sales teams reinforce patient ethical working environment focused business practices schedule global learning programmes stop payments healthcare professionals year make easier employees speak behalf avoid perceived trained values policies regulatory conflicts interest see requirements classify programmes employee performance management living mandatory expected elective ensure key values one six clear expectations used programmes prioritised evaluate individuals performance new performance management system see gsk responsible business supplement behaviour approach continued working suppliers third parties suppliers third parties completion every audit work suppliers develop agents distributors affiliate companies improvement plan address areas concern check plans implemented satisfactorily agreed equity stake play timeframe significant gaps identified may suspend essential role helping us develop terminate work existing supplier decide manufacture distribute products work potential new supplier working third parties also exposes addition ehs audits specialist commercial insurance us risks could harm business company conducted seven assessments review risks supply manage risks expect third parties comply new companywide thirdparty oversight risk management standards quality safety ethics labour rights health programme build established standards systems safety environment third party code conduct currently delivered decentralised way streamline sets expectations work third parties create standardised approach addressing thirdparty risk across business audit teams manage regularly assess performance suppliers support manufacturing supply supplier ehs audits existing potential suppliers chain suppliers assessed quality compliance gsks quality management system americas also audit suppliers ethical environmental health europe safety ehs management systems performance asia increased number ehs audits higher risk supplier facilities created new team total number audits support extensive ehs riskbased auditing across supplier audit counted single audit even multiple siteslocations supplier base includes six ehs human rights labour included practices audits conducted collaboration payment terms pharmaceutical companies part pharmaceutical expect suppliers meet standards also supply chain initiative psci responsibility support paying time know audits see data summary small businesses particular often face cashflow challenges following change standard payment terms suppliers reviewed terms small medium companies resulted exception small medium suppliers small diverse suppliers usa standard payment terms also set dedicated smallbusiness hotline provide advice support smaller suppliersgsk responsible business supplement behaviour ethical conduct preventing bribery corruption deeply disappointing matter global ethics compliance team types policy violations bribery corruption go values us illegal activities gskci clear manages investigations reported concerns put business reputation risk breach gsks governance compliance provides tools oversight guidance therefore take zero tolerance approach procedures wholly contrary improve compliance formed attendancepayroll values standards expected abac investigations committee oversee antibribery corruption abac code conduct employees published statement allegations bribery corruption across programme designed prevent noncompliance good manufacturing continued reevaluate effectiveness io tsf pp eo ol pog ley oth ue r c weh bin se ee government g incs rk ea w see ul rs io n vm ea sd tige tu ivb es cta ai pn ati bal li tyv e ost um r e gn lot bto l dpr isa tc rt ibic ue ts io ng poo rad c tices programme ensure robust employees corporate investigations team investigates local work access handbook offers practical focus learning issue regulation violations allegations misconduct including abac g tou pid ra en vc ee n ta nn od n p cro oc pd liu ar ne cs e h aa nt n rc el iu nd foe r cc eo n ot ur ro ls w rece ih fya v e isk se un e st e idp es n ifi ec atp gre kn cs ii v ie nl cy lu ding fraud issues allegations raised p ra mke ot ti og n aa ln ad c tivities number countries currently policy preventing corrupt practices changing engagement activities healthcare training completion followed investigated including professionals expanding review falsification documents people working highrisk areas complete poland syria lebanon monitoring invoicing payments travel expenses mandatory online training additional facetoface training provided relevant use robust compliance systems work closely employees disciplined fraud role risk faced training uses government continue innovate improve policy violations access medicines establish gskci dismissed agreed leave realworld examples help employees build model reform chinas healthcare industry company voluntarily policy violations related skills need identify risks effectively also sought apply appropriate sales marketing codes accounted combat real perceived corruption breaches external codes lessons operations elsewhere given dismissals total disciplined gsk employees complementary gsk found breach external complex global environment employees received documented workers completed additional abac training industry government promotional codes operate continue face risks warning remainder depth covered code times related received verbal warnings conduct training reporting investigating concerns consumer healthcare products mainly speak programme offers people within primary reason increase number breaches national regulations codes dedicated independent audit outside gsk range channels voice disciplinary cases particularly documented advertising remaining breaches related team assess internal controls help concerns report misconduct without fear warnings related code conduct violations prescription products including breaches ensure maintain ethical standards reprisal include telephone internet increased number reports china promotional materials advertising continue invest methods channels run independent external operators strengthening investigate every breach external assuring controls prevent risk enable anonymous reporting concerns monitoring systems introduction code take steps prevent recurrence bribery corruption investigated gsk management quarterly knowledge test sales may include retraining corrective september gsk china investment representatives failure pass test results measures disciplinary action standardised monitor contacts co ltd gskci found guilty according employee receiving documented warning made global compliance management chinese law bribing nongovernment system report potential allegations ask employees remain company following personnel verdict followed investigations questions significantly increased policy violation receive retraining increased initiated chinas ministry public security monitoring activities globally led monitoring support cases retraining june included fine million increase contacts made extended employees colleagues prevent contacts making similar mistakesgsk responsible business supplement behaviour promoting values sales marketing practices transforming creating sales force puts patient secondly changing support directtoconsumer marketing needs first education doctors commitment prescription medicines way compensate modernising way sell market medical education remains unchanged advertise prescription medicines sales representatives medicines transforming business model move away direct sponsorship directly consumers new zealand industry many years individual hcps arms length funding usa directtoconsumer dtc advertising engage changing compensate sales example via thirdparty independent medical prescription medicines permitted healthcare professionals representatives engage healthcare organisations organisations markets dtc advertising governed professionals hcps meet customer needs decide best deliver education dtc communications policy based ensure patients interests come first programmes without influence gsk phrma guiding principles direct consumer made good progress advertisements prescription medicines thirdly longer pay hcps commitments three key areas announced speak prescribers medicines dtc advertising usa reviewed december instead using channels including legal regulatory medical specialists new commitment continue drive values firstly january completed digital realtime applications provide dtc television advertisements submitted based approach sales marketing rollout changes way sales teams information medicines vaccines us food drug administration fda practices across world interests compensated sales professionals around way hcps want want review comment broadcast consumers patients core world longer individual sales targets expert medical doctors within gsk us pharmaceutical business receive instead assessed compensated based also take role talk answer questions notices violation warning letters technical skills scientific knowledge medicines peers fda advertising promotion products progress overview track quality service deliver hcps responsible measured providing us commercial practices policies ensure broader business performance sales teams right information support safe effective sales marketing activities related listening customers ' needs bringing use medicines pharmaceutical products meet legal right gsk resources help improve patient care continue pay hcps nonpromotional requirements high ethical standards usa gsk ranked first among major advisory services clinical research revised policies make pharmaceutical companies hcps value welcome gsks move transform payments governed rigorous controls principlesbased userfriendly bring customer satisfaction survey business model ensure based fair market value also included new criteria must sales marketing employees along met launching dtc promotions new patients interests central every publishing payments made hcps relevant third parties acting behalf must medicines including educating hcps gsk committed publishing payments decision company takes follow code practice promotion new treatments alerting make hcps healthcare organisations customer interactions refreshed upcoming advertising campaign remove potential concerns already several countries including code align values undue gsk influence hcp australia france japan netherlands portugal slovakia uk usa line locally prescribing behaviour bold move agreed government industry association one epf monitor closely standards continue support increased transparency countries industry nicola bedlington associations governments establish specific secretary general european guidelines disclosure example patients forum european federation pharmaceutical industries associations code paymentsgsk responsible business supplement behaviour transparency clinical research sharing information given time aim provide greater access researchers must submit research proposals volunteers patients across countries information design methods results independent review panel ensure clinical trials supports participating nearly clinical trials trials protecting personal data used responsibly within secure work benefit sharing information trials helps information participants register environment end gsk make sure involvement contributes includes summaries trial results studies listed available request medical science advancement medical science patient csrs following improvements researchers also able ask data patient care care contribution helps researchers design utility register studies research teams within gsk beyond better understand year seen increase number pages already accessed data using system disease areas develop new medicines viewed per visit duration visit survey researchers experience shown treatments people need first company provide secure environment meeting key make large amount information publicly researchers detailed data sit behind needs helped us identify areas available gsk first pharmaceutical clinical trial results conduct research improvement also completed audit commitment transparent possible company sign alltrials campaign created online system internal processes place support clinical trial data including publishing research transparency since researchers could request access detailed commitment provide greater access clinical study reports without patientlevel online clinical study register anonymised patientlevel data trials patient level data data outcome trials medicines make available information trials january expanded system conducted gsk within appropriate including result summaries regardless launched wwwclinicalstudydatarequestcom process making available researchers whether outcomes might considered include data companies end access anonymised patientlevel data positive negative gsk nine companies used scientific enquiry system encouraging development gsk became first company make independent system include studies clinical study reports csrs formal reports across industry academia form basis submissions regulatory progress overview progressing well agencies publicly available csrs posted onto register personal information removed coled initiative nonprofit organisation transcelerate biopharma inc develop recommended approach removing redacting personal information csrsgsk responsible business supplement behaviour rigorous patient consumer safety patient safety medicines potential risks well collaborate industry peers regulators conduct trials accordance benefits must identify evaluate healthcare providers patients interested international conference harmonisations number one priority safety concerns ensure risks parties improve communication good clinical practice guidelines trial development testing clearly communicated patients prescribers medicines enhance pharmacovigilance protocols reviewed independent ethics payers regulators science relates detection monitoring committee made medical professionals manufacturing use assessment understanding prevention scientists lay people investigators robust policies governance framework products adverse effects drugrelated power reject stop clinical trial help us detect act adverse side effects problems part efforts improve piloted riskbased monitoring may associated medicines pharmacovigilance process research teams approach uses new techniques identify also apply computerised statistical tools perform benefitrisk evaluations manage emerging risks associated data analyse safety information example life cycle medicines results quality patient safety plan implement identifying unexpected adverse events presented global safety board approach across clinical trials reported disproportionate basis commitment continue ensure replaced multiple departmentspecific tools maintain global risk register share interests safety patients consumers gsks global safety board chaired new global database improve top global risks emerging clinical trials paramount importance way chief medical officer composed senior standardise safety processes help research teams around world design undertake clinical trials physicians scientists makes decisions putting patient safety first clinical research monitor quality safety controls appropriately product quality assurance monitoring product safety issues ensures safety research essential create new better rd employees trained good clinical reporting adverse events ongoing key focus research teams reviews medicines transform lives conduct practice working clinical research product usage benefitrisk evaluations gsk products trials patients healthy volunteers regularly audit trial sites development market also assess potential new medicines continue third parties carrying trials behalf internal risk advisory panel encourage monitor efficacy safety approved ensure high ethical quality safety standards sharing information best practices progress overview progressing well clinical trials conducted highest conducted audits across business ethical standards wherever take place see data summary implemented put patient safety first comprehensive programme managing outsourced activities included training conduct clinical trials countries partners gsks policies practices medicines likely suitable wider community gsk conduct clinical explored use technologies trials investigational medicines country better understand patient adherence medicines known outset intent clinical trials included electronic pursue registration make medicine reminders improve patient adherence trial available use country regimens sophisticated technologies transmit data dose medication released stomach help scientists understand medication usedgsk responsible business supplement behaviour rigorous patient consumer safety continued manufacturing supply combating risks counterfeit products introduced fingerprint endtoend produce two billion packs counterfeit medicines vaccines supply chain serialisation programme apply medicines million doses vaccines healthcare products pose significant threat unique serial fingerprints many products nearly five billion packs consumer patient consumer safety strengthen anticounterfeiting healthcare products every year lack necessary active ingredients quality measures help protect patients consumers controls deliver health benefits claim unique identifiers recorded wellestablished internal framework often contain impurities actually database product scanned place ensure compliance consistency cause harm verified database point reliability quality culture puts patient supply chain end packaging centre efforts deliver right first time counterfeit gsk products originate china lines sites serialisation capability also simplifying rationalising colombia india pakistan peru implement fingerprint across additional processes remove risks could affect quality counterfeited products include sensodyne lines enable product tracking aquafresh toothpastes medicines endtoend supply chain model government reporting augmentin panadol standardising improving controls across counterfeiting crime work closely entire supply chain manufacturing comprehensive global strategy appropriate law enforcement customs operations sourcing raw materials identify prevent counterfeiting tailoring agencies combat largescale often highly making products quality controls packaging solutions requirements specific markets sophisticated counterfeiters sixyear transport customers technological features holograms investigation concluded chinese court security seals complex background patterns well ensuring patient consumer convicted imprisoned group counterfeiters packaging help patients consumers safety commitment high standards manufacturing counterfeit gsk recognise genuine products avoid manufacturing helping us drive progress medicines sale africa also collaborated counterfeits use technology track monitor towards ultimate goal zero accidents zero law enforcement agencies colombia investigate sale counterfeit products defects zero waste see health india pakistan led raids arrests also support fight fakes campaign safety waste underground counterfeiting factories global campaign raises awareness reported cases raids arrests see two gsk manufacturing sites cork dangers counterfeit medicines advocate data summary ireland ste foy canada received governments help stop counterfeits warning letters us fda taking comprehensive actions resolve issuesgsk responsible business supplement behaviour minimising animal testing understand share develop new medicines vaccines encourage uptake rs recognise refine need check desired effect employees make outstanding contributions clear standards processes place ethical concerns safe people use animal welfare silver animal ensure animal welfare office animal surrounding animal need assess affect interactions welfare award went individual whose welfare ethics strategy led chief pathways organs tissues within work showed age animals used veterinary medicine oversees humane research animal studies body makes animal tests critical research may profoundly affect experimental responsible use animals across gsk continue provide vital part research strategy results applying knowledge studies conducted contractors suppliers designing studies fewer animals may needed information adopt rs approach commonly used reduced variability study groups behalf must adhere high across biomedical industry replace animal standards animal welfare adopt findings explored obtained alternative research possible reduce number research animal quality assurance national centre rs animals used study still providing group assessed methods regulations precise information refine techniques used fewer animals organisations care welfare programmes require us test minimise pain improve welfare animals previous year fewer past seven years cases contractors fewer nonrodents fail adopt recommendations show medicines vaccines replace nonhuman primates commitment continuous improvement launched strategic initiative animals starting following site visit stop working potential reduce reliance clinical trials animal studies together european bioinformatics institute sanger institute change animal use vs index year looking new ways develop medicines using human cells tissues well using vitro tests individual cells cultures tissues use computer simulations commitment rigorously challenge need instead animals possible animal studies work minimise impact animal welfare investing reduce development alternative studies sharing continued rigorously challenge animalbased data need animal studies focus rs example studying multiple sclerosis scientists found changes optic nerve used proxy overall nerve progress overview progressing well degeneration instead studying different stages disease multiple animals developing method track loss vision single animal n animals used within gsk facilities n animals used contractors behalf gsk figures normalised first year data formation glaxosmithkline data includes animal research conducted external contractors behalf data unavailable gsk responsible business supplement behaviour addressing human rights impacts support un guiding committed upholding universal activities embargoed countries declaration human rights core labour stakeholders concerns read online principles business standards set international labour businesses operate countries targeted human rights organization gsk also signatory sanctions laws cuba north korea publish detail online key un global compact iran sudan syria clear challenges working address issues including risks company operating independent thirdparty assessment human rights impacts markets believe people gsk antibribery corruption handbook human rights impacts business identified seven priority areas access health denied access medicines gsk policy preventing corrupt practices care air quality impact relating propellants regime operating country aim maintaining standards documentation supply medicines vaccines countries clinical trial standards employment practices gsk antibribery corruption guidelines need wish purchase including patient safety product counterfeiting use third parties essential medicines sanctioned countries thirdparty suppliers commitment address un guiding compliance applicable sanctions export cloning technologies stem cell research principles business human rights work highlighted potential improve controls also comply disclosure disclosure clinical trial information across operations companywide risk management controls requirements iran threat reduction supplier relationships use suppliers continued syria human rights act regularly care welfare treatment animals address new global third party look best address challenges role transgenic animals oversight programme see supplying countries meet biomedical research needs patients progress overview track also identified need provide use nonhuman primates nhps support local markets effectively implement privacy data security discovery development medicines principles global policy equal global privacy principles require vaccines inclusive treatment employees employees suppliers ensure counterfeiting healthcare products worked address greater personal data collected used processed collaboration communication training transferred stored appropriately securely pharmacovigilance see line legal requirements see website criteria working public policy groups summary binding corporate rules safeguarding personally identifiable information global code practice promotion customer interactions code conduct clinical trials developing worldgsk responsible business supplement behaviour ethical interactions regularly interact public policy also trained relevant employees tax engage governments policymakers updated global policy grants donations businesses increasingly challenged political key multilateral agencies professional ensure contribute tax system gsk member many trade stakeholders associations advocate policies protect societies operate industry associations primarily represent interests patients supporting provide information tax management committed pharmaceutical consumer products business example worked principles policies understand vaccine businesses national regional appropriately ethically help advance policies spur innovation responsibility pay appropriate amount international levels see website accelerate pace medical breakthroughs tax fully support efforts ensure companies transparently usa governments st century full list appropriately transparent cures initiative also shared best practices engaging patient advocacy groups tax affairs managed universal mass vaccination strategies engage support patient groups substantial business employment gain insights patients help us develop authorities national immunisation technical presence many countries around globe products advocate policies better advisory groups europe adriatic countries pay significant amount tax including meet needs commitment demonstrate gsk gsk registers costs relating lobbying corporation business taxes well interactions patient advocacy groups eu transparency register us support includes funding staff training tax associated employees political stakeholders conducted federal lobbying register cost educational assistance collaboration time responsibility appropriately ethically transparently representing interests eu institutions disease awareness prevention projects shareholders financially efficient range outlined gsk code practice deliver sustainable tax rate part spent us federal promotion customer interactions grants approach look align investment funding gsk exceed patient progress overview progressing well lobbying activities groups annual revenue exert strategies countries already make corporate political contributions undue influence promote products substantial economic activity us employees choose provide organisations grants patients groups government policies promote tax regimes financial support political groups individual published attractive business investment candidates political action committees pay considerable amount tax uk patient advocacy leaders summits pals pacs federal election campaign act significant proportion global continue build relationships patient gsk employees pac contributed corporate functions rd manufacturing advocates industry health policy experts state federal candidates activities located includes pals events held portugal funds contributed federal corporation tax profits generated well switzerland latvia germany japan serbia candidates funds indirect tax employment taxes although slovenia issues including empowering contributed candidates state offices precise amounts fluctuate year year communities conduct patientcentred care part advocacy efforts work improving access healthcare promoting see annual report details includes running advocacy office brussels salaries appropriate thirdparty policy groups highquality strategies patient advocacy tax payments read ac sn ofe cr ie tic oe ns er mav el ra sn hd ip c fo en es su l nin ag pc ro il ts e tx hc elu rd ae ns g etr pd ue b l ished clearly defined criteria guide selection discussed usa national pals five approach tax website eu register change gsk adjusts calculations groups ensure share values regional pals events focused healthcare e e thtc eh u th se f en dtr eo rd au l c loti bo bn inf gn e rew g ie su te rr u tle hs f fir g uh e r coe vg eis rt se tr h e costs align priorities introduced costs quality pals reached salaries benefits employees registered lobby new standard operating procedures reflect leaders countries since tu hs e gg oo vv ee rr nn mm ee nn tt flo fab irb sy fg fi cc eo n ins u wlt aa sn ht ic gs tots n dre cse ar nc dh uru pn pn oin rtg taff criteria revised existing ones began also includes proportion gsks trade association fees govern interactions government officials associated federal lobbyinggsk responsible business supplement people pulse programme employees opportunity use expertise support nonprofit organisations addressing major global health challenges building skills experience martin brandt volunteered ogra foundation kisumu kenyagsk responsible business supplement people approach ensure right talent engagement working hard attract develop engaging employees mission strategy focus supporting people right skills retain skilled talented people need gives everyone gsk clear sense people integration support business levels organisation track help drive business forward ceo achieve global target recruit students members corporate executive team announced proposed threepart people strategy focuses year onto early talent programmes cet deliver regular live broadcasts transaction novartis transaction four areas talent acknowledging global commitment messages keep employees informed strengthen vaccines consumer increasing apprentice population strategy progress also recognise healthcare businesses result leadership performance decided include early talent importance listening employees acting considerable change employees engagement community alongside future leaders feedback improve experience around novartis employees join graduates esprit postgraduate conducted interim surveys covering around business employee transfers take place programme participants employees indicated managers around countries priorities leadership leading people effectively employees leadership development programmes engagement formal consultation limit number redundancies provide employees levels skills employees representatives unions applying recruitment freezes need become leaders management works councils particularly important costsaving measures instances essentials new management periods restructuring continue redundancies unavoidable advanced leading business work closely groups committed offering support advice experienced leaders coaching programmes help employees find new job information performance areas helped participants strengthen found data summary provide clear regular communication leadership capabilities see progress commitments held live briefings local approach leadership leaders ensure employees well healthy workplaces diversity employee performance volunteering covered following pages informed changes may affected briefings also gave improving way manage employees works councils unions employees performance promote individual open culture opportunity raise questions responsibility accelerate delivery concerns us business strategy new global performance people really accept system sets clear objectives people ensure successful cultural integration make point develop aligned delivering strategy conducted interviews senior leaders underpinned six gsk expectations every one way suits organisations survey defining require everyone gsk individual capabilities gsk novartis employees puts emphasis results understand perspectives two also way results achieved choon businesses working cultures enables us better engage motivate marketing sales gsk singapore would like future culture people strengthening connection participant future leaders programme using results develop cultural transformation plan individual performance rewardgsk responsible business supplement people approach continued creating pipeline strong leaders levels business committed supporting experienced highpotential leaders leading leaders developing bestpractice business programme aims equip skills behaviours knowledge mindsets required management capabilities values manage support diverse crosscultural based decision making highperforming teams translating strategy integrated complementary range effective actions business units leadership programmes month period participants undertake immersive experience mumbai london focusing range leadership responsibilities including building better together programmes clarify expected partnerships creating shared value understanding leaders individually community key issues eg access medicines giving delivering strategy helping patients participants firsthand visibility ngo work customers feel better live longer key teaching point leaders working strengthened common language created paradoxes senior roles eg balancing local gsk leadership expectations leadership global needs programmes also ensure exceptional small number leaders demonstrating business diverse leaders levels business practising acumen leadership capabilities appointed inclusive leadership means value draw corporate executive team one direct differing knowledge perspectives experience reports invited participate highly customised styles contained global community twoyear global learning experience bespoke management essentials first line leader enterprise leadership programme intense highly programmes provide new managers thorough experiential programme combining assessment grounding essential management responsibilities coaching training applied learning elements eg performance management ensure introduced new programme enabling confidently take next step careers female leaders enhance network clarify leading delivery programme helps middle career ambitions build confidence managers leading managers translate become strong senior leaders combining personal business strategy action drive performance group coaching senior sponsorship open build capabilities enhance trust team honest dialogues believe programme helps members colleagues organisation make better decisions reducing risk increasing innovationgsk responsible business supplement people protecting health wellbeing people take progressive protecting people also continued reduce potential providing preventive healthcare take progressive approach protecting exposure employees hazardous groundbreaking global partnership approach protecting health wellbeing employees substances example eliminated prevention pp programme aims create health wellbeing sustaining strong health safety culture use formaldehyde fumigation healthier productive workforce across operations important focus vaccine manufacturing processes differentiate gsk employer pp offers people business past ten years information see public policy positions preventive healthcare services halved reportable injury illness hazardous chemicals management immunisations cancer screenings routine rate reduced figure eu reach regulation preventive examinations employees incidents per hours worked families little cost part benefits building employee resilience means achieved target package multinational company global energy resilience year early offer benefits scale commitment continue create working programmes helping employees environment inspires people grow health safety culture ensures employees build mental physical resilience year made good progress towards perform healthy resilient way aware health safety risks lead happier healthier lives home target implement pp globally stay safe work continued invest work programme piloted ecuador ghana leadership training help leaders identify nigeria romania since since global workforce across manage risks effectively implemented middle east turkey progress overview track countries participated one global manufacturing supply leaders pp provides preventive healthcare programmes improve personal resilience countries taking part employees family members research shows participants experience countries increase sustained improvements personal reportable injury illness rate employees family members countries resilience wellbeing long term per hours worked launch pp latin america south plan increase participation energy america early extended resilience programmes roll pakistan countries africa across business offer advice information counselling confidential employee assistance gsks approach promoting energy programme support employees dealing resilience novel wide range personal health wellbeing innovative also contributing professional issues stress financial health individual family problems employees access service bottom line gsk proud working employees emphasise work field confidentiality service overcome social model others cultural issues may make reluctant use professor sir cary cooper cbe distinguished professor organisational psychology health lancaster universitygsk responsible business supplement people promoting inclusion diversity inclusive employer gender diversity disability cultural ethnic diversity aim improve gender balance levels working hard ensure understand ensure leadership teams represent value draw organisation focused creating needs people disabilities diverse markets serve building different knowledge opportunities women management developing employment opportunities talent pipeline includes people range proportion women management continued established global disability council agree cultural ethnic backgrounds eight perspectives experiences increase see chart women priorities set objectives report progress nationalities represented corporate working styles continued represent corporate becoming disability confident organisation executive team board people executive team board gsk employ emerging markets asia pacific global workforce ranked joint fifth uk governments founding member business disability japan represent workforce international bdi social enterprise involving report womens representation boards consumer healthcare business several global businesses gsk helping ftse companies india pharmaceutical business latin develop global standards measure businesses america made particularly good progress employeeled womens leadership disability performance attracting developing local talent initiative brought together people addition efforts global level commitment continue promote gsk senior leaders first global also increased proportion people involved local initiatives ensure inclusion diversity globally gsk conference encourage action emerging markets participating recruitment process inclusive people accelerating womens career development development programmes joining disabilities example company graduate mba accelerating difference female japan joined accessible recruitment programmes addition development progress overview progressing well managers completed individual group search engine called accessibility new regional headquarters singapore coaching sessions also encourage disabled employees enable us attract develop talent senior leaders sponsor female managers emerging markets developing local talent support career development uk helped young people also important focus africa strategy learning disabilities transition women management positions education employment project see search since svpvp us partnership global director company computer aid inc danish manager company specialisterne start total recruiting people autism services teams gsk responsible business supplement people community volunteering creates change encourage people flagship pulse volunteer partnership encourage employees around world enables employees work full time support local communities offering one volunteer time nonprofit organisation charity three paid day year volunteer expertise support six months builds leadership skills orange day programme orange day projects providing valuable insights expertise included distributing food homeless communities around organisations working address major people malaysia organising careers world healthcare challenges workshop unemployed parents poland maintenance work orphanage since sent employees india countries work nonprofits provided million worth skilled extend employee volunteering bring services partners employees positive change communities volunteered organisations see established new volunteer ambassador pulse volunteer partnership commitment extend volunteering pulse report network includes employees watch video find opportunities bring positive countries working nonprofit partners change communities global health partner organisations volunteers understand needs develop locally providing individual development agree pulse positive impact relevant programmes also raising nonprofit partners something awareness opportunities differently result volunteers read online offer website volunteer agree pulse assignments strengthened progress overview progressing well awareness week leadership skills see employee publish detail online key volunteering section website blog issues including pulse impact pulse assignment hazardous chemical management employees key part global able recognise leverage gsk reach partnership save children since collaborative problemsolving launch campaign may skills ive gained years gsk employees countries raised million lawyer gsk experience matched funding gsk pulse changed realised employees also seconded work offer professional skills save children support partnership charity see community partners trish assistant general counsel worked philadelphia education fund usgsk responsible business supplement planet recovering waste sites singapore using produce electricity steam power jurong site tomas hong yean works cutting carbon emissions waste costsgsk responsible business supplement planet approach committed climate change one worlds gsk recognised vast reducing environmental pressing issues major threat peoples majority environmental impact focus reducing health global economic development environmental impacts business occurs outside impacts operations impacts like extreme weather heat waves affect food production availability clean operational control working closely changing way make antibiotics products water sanitation threaten hardwon looking ways save energy reduce water supply chain gsk showing global health improvements impact waste improve yields reduce real leadership taking meaningful costs whilst maintaining efficacy using resources efficiently action sustainability driving drug achieved reduction collaborating others tackle antibiotics carbon footprint per pack challenges reduce costs change helping companies past five years increasing production enhance competitiveness improve performance volumes set ambitious goals reduce carbon innovation collaboration site irvine scotland water waste across value chain introduced wind turbines two combined tom delay sourcing raw materials impacts heat power plants reduce carbon labs factories use disposal ceo carbon trust emissions energy use also products patients consumers installed anaerobic digester save gsk signatory un caring climate retained position cdps ftse site million year changes mean irvine producing around initiative un ceo water mandate climate disclosure leadership index product using energy partnerships seventh year gsk one two amount water sharing knowledge resources tackle pharmaceutical companies included reduction carbon emissions global environmental challenges together index recognition amount quality climate change data disclosed quality road site singapore recertified gsk remains use penicillin produced irvine make pharmaceutical company achieved amoxicillin one widely prescribed carbon trusts carbon standard water antibiotics introducing new process using standard cutting carbon emissions water enzymes eliminate chlorinated solvents use across operations globally cut amount waste produced reduce carbon emissions site solvent waste recovered used fuel generate electricity steam jurong factory singapore reducing water site worthing uk formulate year year package antibiotic augmentin amoxicillin clavulanic acid putting six tablets foil blister strip instead four reduced foil use pack size enabling us put packs palletgsk responsible business supplement planet approach continued set ambitious target achieve carbon understanding carbon footprint across value chain neutral value chain raw materials operations logistics product use disposal working suppliers investing aim minimise carbon products established inhaler reduce impacts technology efficiency emissions transporting particularly propellantbased recycling programme associated sourcing raw measures renewable products customers inhalers generate carbon engage patients reduce materials well exploring energy reduce carbon using sea freight rather emissions use emissions associated ways use resources emissions energy air redesigning patients consumers disposal products efficiently products use operations packaging make transportation efficient tonnes coe per annum tonnes coe per annum tonnes coe per annum tonnes coe per annum tonnes coe per annum use metered energy dose inhalers tonnes coe per annum tonnes coe per annum hfa process use emissions products tonnes coe per annum tonnes coe per annum business travel tonnes coe per annum total emissions sales force estimated tonnes co e per annum tonnes co e per annumgsk responsible business supplement planet carbon reducing operational performance operational impacts also changing way manufacture reduced scope emissions reducing energy use carbon emissions metereddose inhalers sites spain carbon emissions operational boundaries associated generating energy france reduced amount propellant engaging suppliers million tonnes coe purchase important focus programme used purge air flixotide seretide reduction compared achieved cut environmental impacts ventolin inhalers reduced patients cut emissions continued investment energy efficiency investing infrastructure wind turbines ghg emissions associated process associated sourcing generate renewable energy using waste around tonnes co e per year scope emissions associated fuel energy example ireland innovation recognised ceo raw materials use logistics business travel patients use installed metre wind turbine cut environment health safety sustainability metered dose inhalers use hfa cork sites electrical carbon footprint awards products propellant increased save energy costs overall increase compared singapore installed boiler tackling scope emissions continues fuelled waste jurong quality challenge sales propellantbased road sites provide steam jurong site inhalers continue grow cutting energy costs commitment reduce overall carbon product impacts footprint vs working carbon trust scope ghg emission scope ghg emission carbonneutral value chain since measure certify carbon tonnes coe tonnes coe footprints biggest selling products identify make effective reductions emissions associated progress overview work products example changed process manufacture active pharmaceutical ingredient abacavir used treat hiv reduced products carbon footprint target target gas fuel purchased materials electricity steam product logistics propellant emissions manufacture inhalers business travel air sales force travel propellant emissions use inhalers emissions use products excluding biogenic emissions year according disposal products current guidance accounts decrease emissions estimated datagsk responsible business supplement planet carbon continued supply chain gsk asked wanted take complete cycle working suppliers help reduce complete cycle initiative encourages part energy reduction workshop carbon emissions critical achieving patients customers return old ill honest sceptical carbon goals collected carbon respiratory inhalers participating pharmacies water waste data would actually deliver sent back us recycled largest materials suppliers covering glad agreed reduces waste sent landfill well billion spending raw materials used changes making result prevents remaining propellant used manufacturing rd see inhalers released greenhouse gases approach responsible procurement workshop could reduce energy collect crushing cans also launched gsk supplier use make significant aluminum recycled scheme innovation exchange online forum inroads operating costs also created opportunity pharmacists around suppliers collaborated share talk patients managing next three years practical ideas improving energy efficiency use products condition us pilot ways sharing reducing water use suppliers used definitely worth use products metered dose information inhalers collected local insight make improvements operations inhalers accounts carbon emissions healthcare service providers helps inform head engineering across value chain carbon patient education reduces medicine waste also offered run workshops selected aesica pharmaceuticals trust certified carbon footprints three suppliers sites help identify launched complete cycle respiratory products according ways reducing energy use running six countries greenhouse gas accounting sector guidance community hospital pharmacies participating recognise suppliers efforts reduce pharmaceutical products medical uk alone environmental impacts new devices footprinting compared relvarbreo gsk supplier environmental sustainability ellipta seretide accuhaleradvair diskus award packaging supplier alba dry powder inhalers seretide evohaler scheme created new supplies gsk tubes advair hfa metereddose inhaler opportunity pharmacists talk toothpaste award comprehensive results show thoughtful energy efficiency programme patients managing design newer dry powder ellipta inhaler containing relvarbreo reduced carbon condition piloting ways footprint one days treatment least sharing information inhalers versus older inhalers shared collected local healthcare services product footprints uk nhs national formulary denmark help inform patient education reduce medicines wastage nikki yates head uk pharmaceuticalsgsk responsible business supplement planet water working reduce performance operational impacts operational water use year year cut operational water use use million water water impact associated million reduction per year operations research products baseline means met target laboratories manufacturing sites offices cut operational water use year early systematically audit sites identify opportunities cut water use measuring reducing wider water impact audited four highest water use sites across value chain amount india italy singapore three use challenging areas water scarcity cut wateruse commitment reduce water completed extensive assessment identify average sites activities highest water impact impact across value chain example introducing water efficient across value chain prioritised efforts vs cleaning procedures identifying repairing mapping water impact across value chain leaks investing efficient equipment water consumption one dimension reducing water use remains important progress overview progressing well w bea ete nr wim op rka ic nt g wiv te hr e xh te e rp na l e xw po e ry te ar ns w ne g ha ov se factor also developed tool ta rg e carbon trust determine wider water identify factors contribute total impact sites began water impact piloting tool eight sites globally including use products water scarcity amount freshwater site india significant water impact estimate gsks value chain available basin relation demand generating water impact score tool water impact consumer use clearly identifies sites main impacts products particular people leaving tap local water quality level pollution offers guidance help put improvement running cleaning teeth freshwater sources threats plans place extended turn tap campaign biodiversity result including adding logo labelling sensodyne release pharmaceuticals operations supply chain toothpaste brand uk supply chain uses estimated health social risks peoples access million water raw materials horlicks clean water improved sanitation carbohydrates sugars wood derived products regulatory reputational risks level eggs account water impact water governance regulatory risk related partnered teri ngo india water develop diagnostic water impact tool combining indicators water used identify opportunities consumption data wwf water ten largest suppliers reduce water risk filter developed global water impact impacts work suppliers tool used identify hotspots across teri extend process value chain suppliersgsk responsible business supplement planet waste goal halve performance australia example increased operational waste generated goal halve operational waste amount ethanol recovered port fairy site operational waste thousand tonnes actively eliminating reusing recycling litres reusing ethanol washing waste well generating energy waste processes maintaining product quality generated tonnes waste also saved business adopting four simple operations less per year operating costs steps eliminate reuse less continuing continue look innovative ways reduce explore ways cut waste individual sites recycle generate help us achieve target halving recycle waste sites around world example received regulatory approval operational waste energy waste compost tonnes per year egg waste order priority total waste went landfill generated manufacturing flu vaccine three sites achieved zero waste sainte foy site canada instead sending landfill status bringing total sites landfill egg waste mixed represents manufacturing green waste sold compost major research development sites commitment new ideas find beneficial uses recognise work waste include sending packaging waste commitment reduce achieve zero landfill sites total waste generated thousand tonnes poznan site poland make construction changed way report waste longer operational waste vs operational waste material waterproof flooring running include solvent waste recycled reused site part total waste generated recognise need continue reducing pilot recover aluminium waste waste even business grows toothpaste tubes site maidenhead uk processes use manufacture medicines progress overview work complex highly regulated multiple governments across globe take read online several years introduce major changes improve manufacturing processes reducing publish detail online key hazardous chemical management amount waste generated see issues including ozone depletion metereddose inhalers avoid producing waste climate change asthma recognise waste value aim avoid sending waste landfill genetically modified microorganisms pharmaceuticals environment disposal positive benefit environment health safety ehs use ozone depleting substances ancillary instead focused moving waste gsk reach plant equipment hierarchy seeking opportunities reuse gsk convention biological diversity green chemistry greener processes labs possible recycling incinerating generate energy starting see gsk public policy nanotechnology assurance statement progress proportion waste recycled disposed positive benefit increased gsk responsible business supplement data summary health notes community investment global community investment million million million million strengthening healthcare systems reinvestment ldcs million million million million neglected tropical diseases albendazole tablet donation lf elimination soiltransmitted helminths million million million million behaviour notes compliance employees disciplined policy violations employees dismissed agreed leave company voluntarily documented warnings violations sales marketing policies subsequent dismissal breaches external codes number contacts made speak channels see information clinical trial data publicly available trial result summaries cumulative number clinical study reports posted register number trials listed data available request number research teams approved data requests accessing gsk trial data may dec clinical research clinical quality assurance assessments audits investigator sites conducting gsksponsored trials audits gsk processes audits contract research organisations carry clinical trials behalf audits gsk local operating companies involved clinical trial activities investigations suspected irregularities inspections gsk sites regulatory authorities anticounterfeiting number reported cases counterfeiting number raids law enforcement agencies regulatory authorities number arrests law enforcement agencies regulatory authorities gsk responsible business supplement data summary continued people notes number injuries illness lost time losttime injury illness rate per hours worked reportable injury illness rate per hours worked number nearmiss incidents nearmiss incidents reported globally data relate results pilot project global manufacturing supply number fatalities fatality occurred employees motor cycle hit suv carrying overtaking manoeuvre talent leadership development number leaders completing leading delivery programme total number coaching assignments number graduates recruited previously reported combined figure number employees completing postgraduate esprit programme previously reported combined figure number apprentices recruited inclusion diversity percentage women management total percentage employees emerging markets asiapacific japan volunteering number employees completing pulse data restated actual data available replace estimated data reported previouslygsk responsible business supplement data summary continued planet data notes carbon scope ghg emissions tonnes coe estimated data gas fuel electricity steam propellant emissions manufacture inhalers sales force travel emissions excluding biogenic emissions according current guidance accounts decrease emissions total scope ghg emissions tonnes coe purchased materials estimated data product logistics business travel air propellant emissions use inhalers use products estimated data disposal products estimated data total water net water consumption operations million cubic metres estimated net water use value chain million cubic metres waste total waste generated thousand tonnes waste landfill thousand tonnes compliance internal audits number environmental fines see footnote environmental remediation spend million take responsibility removing pollution contaminants soil surface ground water facilities used previously disposal sites waste management companies used followup inspection upper merion site regulator discovered waste tank installed comply local regulations resulting fine levied due longevity noncompliance waste tank taken service surveyed us sites confirm compliance regulations settlement fine paid hamilton site failure submit risk management plan storage use chloroform site cooperated us epa resolving matter promptly submitting viable plan memphis site selfdisclosed errors omissions annual air emissions results penalty levied upgraded air emission control systems improved reporting procedures site ensure compliance upper providence site selfdisclosed failure comply recordkeeping requirements penalty levied improved reporting procedures ensure compliancegsk responsible business supplement summary assurance statement bureau veritas summary independent opinion recommendations gsks response assurance assurance statement result verification conducted per pleased bureau veritas findings reporting bureau veritas uk limited engaged scope work bureau veritas opinion gsks established processes managing gsk plc provide independent assurance gsks ehs performance data ehs data committed continue report performance annually environment health safety ehs improving ultimate goal providing report part commitment provide fair summary ehsrelated performance data accurate ehs data public open transparent activities performance prepared gsk plc objective bureau website continue business activities responsible business veritas work express opinion contain performance metrics information work towards improving data accuracy also covered annual report accuracy reliability ehs data based established collection emphasis incorporating data coverage provide summary findings collation processes deemed recommendations provided bureau data report relates gsks free significant error omission bias veritas implementation new full assurance statement found global operations calendar year reporting system seen improvement includes details scope work quality data evidenced site except otherwise stated data reporting many areas business methodology findings recommendations consolidated level seen based data environment health data responsible business improvement date recently implemented data safety sections independently supplement used sites improve summary scope methodology management system ehs central management ehs programmes verified bureau veritas brand names assessment performance data contained supporting processes guidance continue working sites appearing italics throughout report within ehs data table associated implementation ehs central improve data submission including trademarks owned andor licensed data management processes involved comprehensive effective providing comments explanation gsk associated companies detailed review integrity selected refinement ehs reporting trends complete timely fashion reporting standards datasets aggregation checking inclusion complete ehs data index global reporting processes corporate level well commercial operations business initiative guidelines shows elements sampling data back source five gsk review supporting guidance fully meet covered report signatory sites sites chosen represent requirements new system completion un global compact publish annual significant impact gsk operations revised approach detection communication progress demonstrate geographical spread anomalies consolidated ehs datasets uphold ten principles interviews senior ehs staff statement independence impartiality feedback counts understand gsks objectives approach competence welcome feedback data management bureau veritas independent professional responsible business performance services company specialises quality reporting please contact us environmental health safety social csrcontactgskcom also request accountability years history receive regular updates progress assurance team extensive experience environmental social ethical health safety information systems processes bureau veritas code ethics ensures staff members avoid conflict interest maintain high ethical standards business activities london february